966 related articles for article (PubMed ID: 33956843)
1. High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
Cota JM; Benavides TM; Fields JD; Jansen N; Ganesan A; Colombo RE; Blaylock JM; Maves RC; Agan BK; Okulicz JF
PLoS One; 2021; 16(5):e0250607. PubMed ID: 33956843
[TBL] [Abstract][Full Text] [Related]
2. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database.
Patel N; Borg P; Haubrich R; McNicholl I
Am J Health Syst Pharm; 2018 Aug; 75(15):1132-1139. PubMed ID: 29903710
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.
Baecke C; Gyssens IC; Decoutere L; van der Hilst JCH; Messiaen P
Neth J Med; 2017 Jul; 75(6):235-240. PubMed ID: 28741582
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study.
Schlaeppi C; Vanobberghen F; Sikalengo G; Glass TR; Ndege RC; Foe G; Kuemmerle A; Paris DH; Battegay M; Marzolini C; Weisser M;
HIV Med; 2020 Jan; 21(1):53-63. PubMed ID: 31532898
[TBL] [Abstract][Full Text] [Related]
5. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
6. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with erectile dysfunction diagnosis in men with HIV infection: a case-control study.
Jansen N; Daniels C; Sunil T; Xu X; Cota J; Ganesan A; Agan BK; Okulicz JF
HIV Med; 2021 Aug; 22(7):617-622. PubMed ID: 33899322
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
9. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Majeed SR; West S; Ling KH; Das M; Kearney BP
Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
[TBL] [Abstract][Full Text] [Related]
10. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy.
Peng AT; Huang SH; Lee HY; Wu PY; Kuo HY; Hung CC
Int J Antimicrob Agents; 2024 Feb; 63(2):107067. PubMed ID: 38141835
[TBL] [Abstract][Full Text] [Related]
12. Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor.
Lin KY; Cheng CY; Yang CJ; Tsai MS; Hsieh SM; Sun HY; Sheng WH; Chen MY; Chang SY; Cheng SH; Hung CC
J Infect Chemother; 2014 Aug; 20(8):465-70. PubMed ID: 24855915
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
14. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
15. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
Porst H
Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
[TBL] [Abstract][Full Text] [Related]
16. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
17. Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study.
Zaman Huri H; Lian Choo T; Sulaiman CZ; Mark R; Abdul Razack AH
BMJ Open; 2014 Jul; 4(7):e005381. PubMed ID: 25001396
[TBL] [Abstract][Full Text] [Related]
18. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
[TBL] [Abstract][Full Text] [Related]
19. Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France.
Demessine L; Peyro-Saint-Paul L; Gardner EM; Ghosn J; Parienti JJ
Open Forum Infect Dis; 2019 Mar; 6(3):ofz051. PubMed ID: 30949521
[TBL] [Abstract][Full Text] [Related]
20. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
